Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus HALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus HALOG.
COR-OTICIN vs HALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Halcinonide is a synthetic corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokine production.
1-2 drops in each affected ear twice daily for 7 days.
0.01-0.025% cream or ointment applied topically to affected area twice daily for 2-4 weeks.
None Documented
None Documented
Clinical Note
moderateCephaloglycin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cephaloglycin."
Clinical Note
moderateCephaloglycin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cephaloglycin."
Clinical Note
moderateWarfarin + Cephaloglycin
"Warfarin may increase the anticoagulant activities of Cephaloglycin."
Clinical Note
moderatePhenprocoumon + Cephaloglycin
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 48–72 hours. Prolonged half-life allows once-daily to twice-weekly dosing; requires careful tapering to avoid adrenal suppression.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal (≈65% as metabolites, <1% unchanged), with biliary/fecal elimination (≈35%, including enterohepatic circulation).
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid
"Phenprocoumon may increase the anticoagulant activities of Cephaloglycin."